Genmab — November 2017

[E_L]

NCT03301220 NOW RECRUITING (Brief title: A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma)

[E_L]

NEW: NCT03346135 Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma https://clinicaltrials.gov/ct2/show/NCT03346135?term=daratumumab+OR+ofatumumab&lupd_s=11%2F16%2F2017&rank=2

[Mcjean]

Ty Stockbull and E L

[henrik48]

God morgen og mange tak til Stockbull og E L

[StockBull]

@El. Its from Nov. 9 after Genmab Q3 when J.P.M reduced from 1400 to 1330. They cut the salesforecast 2017-21 by 10%

[E_L]

ok thanks. i forgot they reduced a 2nd time

[StockBull]

Formoder J.P.M holder sig tæt op ad J&J salgsestimat på 7B usd for 2021

[StockBull]

Quote: Analysts forecast Darzalex sales of $3.9 billion in 2021, vs. J&J's comments, which suggest a sales potential of at least $7 billion that year.

[StockBull]

Quote: Darzalex is likely to be used in combination with Celgene's leading multiple-myeloma drug, Revlimid, which is slated to have sales of $12 billion in 2021. Genmab earns a tiered royalty on Darzalex sales, with the highest rate of 20% payable on net sales above $3 billion achieved in a calendar year. (08/16/17)

[JKY_VH]

God formiddag og tak SB og E L

[Bulder]

Plesner kørte sit eget lille ISS-studie ovre i Vejle med 4 pts, men med et interessant formål: Daratumumab is a new treatment for patients with myeloma. While many patients benefit from this treatment some do not and the mechanism(s) of failure are poorly understood. This study aims to clarify aspects of resistance to treatment with daratumumab in order to improve patient outcomes in the future.

[Bulder]

Dette studie er nu afsluttet https://clinicaltrials.gov/ct2/show/NCT02419118?term=daratumumab&cntry1=EU%3ADK&rank=1

[Bulder]

Gad vist om vi hører nærmere?

[Bulder]

Mere grus i maskineriet for PD-1 og PD-L1: http://onkologisktidsskrift.dk/behandlinger/660-kraeftbehandlinger-medforer-reumatologiske-sygdomme.html

[Helge_LarsenPI-redaktør]

Ingen "roser uden alvorlige torne" i den terapi.

[rex_pacis]

Hvem udover BMS har eller udvikler produkter indenfor det?

[Bulder]

Roche-Tecentriq. Astrazeneca-Imfinzi.Merck-Keytruda.

[Bulder]

Og så fik vi det på dansk: Kontrolpunkthæmmer.

[rex_pacis]

tak @Bulder

[Bulder]

I øvrigt måske en ide at følge med i Myelomatosebladet. Myelomatoseforeningen har i torsdags haft seminar, hvori bl.a. indgik et foredrag af Nicolai Grønne fra Herlev om Vaccination og CAR-T imod Myelomatose. Der plejer at kommer omtale med slides i bladet efterfølgende. Nogen gange har de også optaget videoer. Det ville jo være det bedste. https://www.myelomatose.dk/content/uploads/2017/08/Myelomatosebladet-Sep-2017.compressed.pdf